ArticleOrphanet journal of rare diseases2025
Diagnostic impact of whole exome sequencing in neurometabolic disorders in Syrian children: a single center experience.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChildhood neurometabolic disorders encompass a range of heterogeneous conditions often presenting with atypical or overlapping symptoms, making accurate diagnosis challenging, time-consuming, and costly. Whole exome sequencing (WES) has recently become a valuable diagnostic tool for suspected genetic or idiopathic neurometabolic disorders. This study evaluates the diagnostic utility of WES in Syrian patients with neurological and metabolic disorders, marking the first report of WES outcomes in this context.
resultsAmong 54 patients, 42 (78%) were from consanguineous families, of whom 38 (90%) had positive WES results. WES identified pathogenic or likely pathogenic variants in 28 patients (52%) and discovered 14 novel mutations. Seventeen patients (31%) had variants of uncertain significance (VUS) aligning with their clinical presentation, and nine (17%) had negative results. WES provided clinically relevant information for 45 patients (83%), with a definitive diagnosis in 28 (52%). Additionally, WES led to diagnostic changes in 45 cases (83%) and treatment alterations in 40 cases (74%).
conclusionOur findings demonstrate the high diagnostic yield of WES and its substantial impact on clinical outcomes. WES has facilitated changes in diagnosis, treatment adjustments, prognostic modifications, and preventive measures, supporting its utility in undiagnosed neurometabolic diseases. This study advocates for WES in pediatric neurometabolic cases, particularly where consanguinity is present.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.